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INTRODUCTION
The clinical relevance of peripheral arterial 
disease (PAD) stems not only from its well-
known debilitating symptoms and sequelae 
(such as intermittent claudication, ischaemic 
rest pain, and limb amputation) but also 
from its position as a strong predictor of 
future cardiovascular (CV) events. PAD 
is a marker of systemic atherosclerosis; 
regardless of whether it is symptomatic 
or not, it has been repeatedly associated 
with a three- to six-fold increased risk of 
death from CV causes.1 Furthermore, this 
increased risk is independent of, and in 
addition to, that expected by concomitant 
traditional CV risk factors.2 The evidence 
is sufficiently robust that national and 
international guidelines recommend the 
same strategy of CV risk modification for 
PAD as for coronary artery disease.3–5 The 
disease, however, is underdiagnosed and 
this may be partly attributed to the fact that 
up to two-thirds of patients with PAD in 
the community are asymptomatic.4 This has 
resulted in calls for the instigation of primary 
care PAD screening via ankle–brachial index 
(ABI) measurement.
The ABI is a measure of the ankle systolic 
blood pressure relative to central aortic 
blood pressure (approximated by measuring 
the brachial systolic pressure). An ABI of 
≤0.9 is considered diagnostic of PAD, a cut-
off point that has been shown to be >95% 
sensitive in detecting angiogram-positive 
disease and approximately 99% specific in 
identifying healthy subjects.6 
Studies have demonstrated that an 
abnormal ABI (≤0.9 or >1.3) is highly 
prevalent among individuals not considered 
at high risk of CV events, as defined by 
CV risk scoring systems such as the 
Framingham Risk Score (FRS).7 According 
to Grøndal and Lindholt, nearly 25% of CV 
deaths occur in individuals believed to have 
low CV risk according to traditional risk 
stratification models;8 this has resulted in 
suggestions that the ABI, as a non-invasive 
and inexpensive test, could be added as an 
additional risk parameter to CV risk tools 
and/or algorithms.1
Current perspectives of PAD screening 
in the UK appear to be mixed: although 
UK general practices are awarded Quality 
and Outcomes Framework (QOF) points 
for having a register of patients with PAD 
and for meeting PAD-related targets, 
there is no incentive to screen patients 
without symptoms of the disease. Some 
countries (for example, the Netherlands 
and Australia) now offer remuneration for 
ABI measurement in primary care, but this 
is not the case in the UK. Notably, however, 
the UK National Screening Committee’s 
handbook for vascular risk assessment, risk 
reduction, and risk management refers to 
the ABI within a list of emerging novel risk 
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Early identification of peripheral arterial 
disease (PAD) and subsequent instigation of 
risk modification strategies could minimise 
disease progression and reduce overall risk 
of cardiovascular (CV) mortality. However, 
the feasibility and value of primary care PAD 
screening is uncertain.
Aim
This study (the PIPETTE study — Peripheral 
arterial disease In Primary carE: Targeted 
screening and subsequenT managEment) aimed 
to determine the value of a proposed primary 
care PAD screening strategy. Outcomes assessed 
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brachial index (ABI)-defined PAD (ABI ≤0.9) with 
QRISK®2-defined high CV risk (≥20).
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Tydfil, Wales. 
Method
In total, 1101 individuals with ≥2 pre-identified CV 
risk factors but no known CV disease or diabetes 
were invited to participate. Participants underwent 
ABI measurement and QRISK2 assessment, 
and completed Edinburgh Claudication 
Questionnaires. 
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A total of 368 people participated in the study 
(participation rate: 33%). Prevalence of PAD 
was 3% (n = 12). The number needed to screen 
(NNS) to detect one new case of PAD was 31. 
Refining the study population to those aged 
≥50 years with a smoking history reduced the 
NNS to 14, while still identifying 100% of PAD 
cases. Of participants with PAD, 33% reported 
severe lifestyle-limiting symptoms of intermittent 
claudication that warranted subsequent 
endovascular intervention, yet had not previously 
presented to their GP. The QRISK2 score predicted 
high CV risk in 92% of participants with PAD.
Conclusion
The low PAD yield and the fact that QRISK2 was 
largely comparable to the ABI in predicting high 
CV risk suggests that routine PAD screening may 
be unwarranted. Instead, strategies to improve 
public awareness of PAD are needed.
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Primary care screening for peripheral arterial 
disease: 
a cross-sectional observational study
factors, but reports that there is insufficient 
evidence to justify its inclusion in risk 
assessment scores at present.9 The concept 
of early identification of CV risk factors and 
disease emerges as a pivotal theme in the 
UK Department of Health’s Cardiovascular 
Disease Outcomes Strategy, with particular 
reference to PAD.10
This study (the PIPETTE study — 
Peripheral arterial disease In Primary 
carE: Targeted screening and subsequenT 
managEment) aimed to determine the value 
of a proposed primary care PAD screening 
strategy. The outcomes assessed were: 
• prevalence of undiagnosed PAD/yield 
from screening; and 
• agreement of ABI-defined PAD (ABI ≤0.9) 
with a QRISK®2-defined high CV risk 
(score ≥20).
METHOD
This prospective observational study was 
based in a large general practice (11 426 
patients) in Merthyr Tydfil, Wales. This is an 
area with high levels of deprivation, adverse 
health behaviours, and morbidity.11 
The study population was chosen on the 
premise that screening should allow the 
identification of patients who would stand 
to benefit from any PAD diagnosis (defined 
as ABI ≤0.9 for one or both legs) and 
subsequent treatment; those with diabetes 
or known cardiovascular disease (CVD) 
were excluded as they should have already 
been targeted for secondary preventive 
strategies. Full inclusion and exclusion 
criteria are outlined in Box 1. 
Figure 1 outlines the recruitment 
process. In total, 1101 individuals with ≥2 
pre-identified CV risk factors (the first of 
these was always age related, that is, male 
≥45 years, female ≥55 years) but no known 
CVD (including known PAD) or diabetes 
mellitus were identified via a search of the 
practice’s electronic patient database and 
invited by letter to participate. No attempt 
was made to contact non-responders. 
Written, informed consent was gained from 
each participant.
Difficulty recruiting to health research in 
primary care is well documented and can 
be partly attributed to logistical factors such 
as domestic and/or work issues, illness, 
and transport.12 Furthermore, attendance 
to screening declines with age; conversely, 
PAD incidence increases with age.8 This 
study aimed to address these issues by 
offering participants the option of being 
seen at home or at their medical practice. 
Participant medical records were 
reviewed for past medical history and current 
medications. Participants underwent 
physical examination — the components 
of which are detailed in Box 2 — and were 
assisted by the research nurse to complete 
the Edinburgh Claudication Questionnaire 
(ECQ), which is an established, validated, 
intermittent claudication diagnosis tool.13 
All measurements, including ABIs, 
were undertaken by the research nurse. 
Participants were asked about their current 
smoking status and alcohol intake. A venous 
blood sample was obtained from those who 
were found to have PAD following 12 hours 
of fasting, and analysed to determine the 
fasting glucose level and lipid profile. The 
QRISK2 CV risk algorithm was used to 
calculate a 10-year CV risk score for each 
How this fits in
Routine PAD screening and subsequent 
appropriate treatment could minimise 
progression of the disease and reduce 
overall cardiovascular (CV) risk. This study 
has shown that targeting individuals aged 
≥50 years who have a history of smoking 
could be an effective and efficient PAD 
screening strategy; however, results also 
suggest that QRISK2 could be a more 
amenable and comparable alternative 
for the identification of high CV risk in the 
primary care setting. 
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Box 1. Study inclusion and exclusion criteria
Inclusion criteria
•  Males aged ≥45 years or females aged ≥55 years (age-related CVD risk factor);
• At least one additional CVD risk factor from the following:
–  cigarette smoking or regular exposure to passive smoke (that is, living with a smoker);
–  hypertension (systolic blood pressure of ≥140 mmHg, diastolic blood pressure of ≥90 mmHg, or 
taking antihypertensives);
–  Low high-density lipoproteins (<1.0 mmol/L), high low-density lipoproteins (>3.3 mmol/L), high 
triglycerides (>1.7 mmol/L), or taking lipid-lowering medication;
–  family history of premature coronary heart disease (first-degree male relative aged <55 years, first-
degree female relative aged <65 years);
–  elevated waist circumference (≥102 cm in non-Asian males, ≥90 cm in Asian males, ≥88 cm in non-
Asian females, ≥80 cm in Asian females);
–  BMI of >25; 
• Willingness to participate in the study.
Exclusion criteria
• Diabetes mellitus (type 1 or 2);
•  Known coronary heart disease, including history of myocardial infarction, angina (stable or unstable), 
coronary artery procedures (coronary artery bypass graft or percutaneous coronary intervention), or 
evidence of clinically significant myocardial ischaemia;
•  Known cerebrovascular disease (for example, history of transient ischaemic attack or stroke);
• Known peripheral arterial disease;
•  Known non-coronary forms of atherosclerotic disease (for example, abdominal aortic aneurysm);
•  Serious or unstable medical or psychological conditions that, in the opinion of the investigator or 
patient’s GP, would compromise the patient’s safety or successful participation in the study;
•  Current or recent (preceding 4 months) participation in a clinical research trial (this does not apply to 
participation in non-interventional research);
• Patient who is unwilling or unable to provide informed consent.
BMI = body mass index. CVD = cardiovascular disease.
participant. For those participants who did 
not have a blood sample taken (no PAD), 
or for whom data were missing, the most 
recent data in their medical record were 
used to calculate their QRISK2 score. 
Statistical analysis
Data analysis was performed using 
statistical software SPSS (version 21). 
Categorical data were assessed using the χ2 
test or Fisher’s exact test. Continuous data 
were assessed using an independent t-test 
or Mann–Whitney U test (as determined 
by the Shapiro–Wilk test of normality). 
Significance was set at P<0.05.
RESULTS
Data from 368 out of a possible 1101 
Age: male ≥45, female ≥55
Pre-existing CVD/PAD or diabetes?
Presence of ≥1 additional cardiovascular risk factor?
No: n = 3442
Yes: n = 3097
No: n = 6490
No: n = 1494
No: n = 345
All patients registered at
     general practice:
n = 11 426
Yes: n = 4936
First 1225 patients from list of 3097
reviewed by PI (who was also patient’s
GP) to determine suitability for
participationa
1101 patients invited to participate
Agreed to participate: n = 369
Final sample:  n = 368
Withdrew consent: n = 1
Declined to participate:
n = 732, mean age: 66 years (SD 12 years, range 45–94 years), 
male:female ratio: 52:48
Exclusions: n = 124
Reasons for exclusion:
Unable to consent: n = 28
Comorbidities (for example, cancer) made participation inappropriate: n = 30
Considered too frail: n = 18
History of aggression:  n = 3
Died since electronic list compilation: n = 27
Diagnosis of CVD/diabetes since list compilation: n = 18
Exclusions
Figure 1. Recruitment process.  
aTime and financial limitations of the study 
prevented invitation and consideration of full list 
of 3097 patients. CVD = cardiovascular disease. 
PAD = peripheral arterial disease. PI = primary 
investigator. SD = standard deviation. 
Box 2. Components of physical assessment 
• Height: without shoes, measured in metres using a Seca Leicester Portable stadiometer;
•  Weight: without outer clothes and shoes, measured in kilograms using Seca 877 floor scales for mobile 
use (class III); 
•  Waist circumference: undertaken according to the World Health Organization’s data-gathering protocol;14 
•  Hip circumference: undertaken according to the World Health Organization’s data-gathering protocol;14 
•  Blood pressure: measured using a Welch Allyn® aneroid sphygmomanometer and stethoscope, in 
accordance with British Hypertension Society guidelines for blood pressure measurement;15
• Pulse: by palpating the radial pulse and counting the number of pulses for a 1-minute period;
•  Assessment for clinical signs of PAD: reduced or absent pulses in legs/feet, thickened nails, smooth 
shiny skin, hair loss to legs/feet, pallor or cyanosis to legs/feet, pallor on elevation of legs, legs/feet 
appearing flushed in a dependent position, reduced temperature to one or both legs/feet;
• ABI measurement: according to the American Heart Association scientific statement.16
ABI = ankle–brachial index. PAD = peripheral arterial disease.
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participants were collected, giving a 
participation rate of 33%. Most participants 
(63%) chose to be seen at home; the 
remaining 37% were seen at the medical 
practice. Population characteristics and 
physical assessment results are presented 
in Table 1. 
The prevalence of PAD within the study 
population was 3% (n = 12). Of these, 42% 
(n = 5) reported symptoms of intermittent 
claudication and had a positive ECQ result; 
80% of those five individuals (n = 4) reported 
severe lifestyle-limiting intermittent 
claudication that warranted referral to 
a vascular surgeon and subsequent 
endovascular intervention (angioplasty). 
None of these participants had previously 
reported their symptoms to their GP as they 
regarded them as a ‘normal part of ageing’ 
or a sign of a lack of physical fitness. 
Factors found to be significantly 
associated with PAD included: 
• advancing age (P = 0.02); 
• current smoking (P<0.01); 
Table 1. Population characteristics and physical assessment results
 PADb No PADc All  
 n = 12 n = 356 n = 368 P-value
Age, yearsa 70.6 (±9.6) 56–86 63.6 (±8.2) 45–85 63.8 (±8.3) 45–86 0.02d
Male:female sex ratio 58:42 54:46 55:45 0.54e
White British ethnicity, %  100 100 100 NA
Smoking status, n (%)    <0.001f  
 Current smoker 6 (50) 37 (10) 43 (12)  
 Ex-smoker 6 (50) 125 (35) 131 (36) 
 Non-smoker 0 (0) 194 (54) 194 (53)
Family history of premature CHD, n (%) 2 (17) 94 (26) 96 (26) 0.53f
Systolic BP, mmHg 144 (±10) 130–160 140 (±16) 98–198 140 (±16) 98–198 0.18d
Diastolic blood pressure, mmHg 76 (±13) 54–98 81 (±9) 40–113 81 (±10) 40–113 0.15d
Hypertension, defined as raised  10 (83) 268 (75) 278 (76) 0.1e 
systolic and/or raised diastolic BP  
and/or on medication for hypertension, n (%)
Pulse pressure, mmHg 68 (±10) 52–88 59 (±14) 30–106 59 (±14) 30–106 0.008d
Heart rate, beats per minute 80 (±16) 58–103 74 (±12) 40–114 74 (±12) 40–114 0.095g
Dyslipidaemia, n (%)  
 Yes 11 (92) 246 (69) 257 (70) 0.23e 
 No 1 (8) 74 (21) 75 (21) 
 No data available 0 (0) 36 (10) 36 (9)
Triglycerides >150 mg/dL or  3 (25) 116 (33) 119 (32) 0.55f  
1.7 mmol/L, n (%)
HDL <40 mg/dL or 1.0 mmol/L, n (%) 0 (0) 35 (10) 35 (10) 0.62f
LDL ≥130 mg/dL or ≥3.3 mmol/L, n (%) 3 (25) 137 (38) 140 (38) 0.22e 
Taking lipid-lowering medication, n (%) 7 (58) 76 (21) 83 (23) 0.03f 
BMI, kg/m2 27 (±4) 22–37 30 (±5) 19–54 29 (±5) 19–54 0.07d
Waist circumference, cm 98 (±11) 83–114 100 (±14) 64–143 100 (±14) 64–143 0.566d
Total number of CV risk factors 4 (±1) 3–5 3 (±1) 1–5 3 (±1) 1–5 0.016g
Chronic kidney disease, n (%) 0 (0) 11 (3) 11 (3) 1.0f
Atrial fibrillation, n (%) 1 (8) 10 (3) 11 (3)  0.29f
Rheumatoid arthritis, n (%) 2 (17) 5 (1) 7 (2) 0.019f
QRISK®2 score 32 (±12) 11–59 18 (±10) 3–58 19 (±11) 3–58 0.001d
Relative risk according to QRISK®2 1.6 (±0.6) 1.1–2.9 1.3 (±0.6) 0.6–5.6 1.3 (±0.5) 0.6–5.6 0.016d
≥1 clinical sign(s) of PAD, n (%) 9 (75) 64 (18) 73 (20) <0.01e
Positive ECQ score, n (%) 5 (42) 6 (2) 11 (3) <0.01e
aUnless otherwise stated, data are presented as mean, standard deviation, range. bABI ≤0.9. cABI >0.9. dMann–Whitney U test. eχ2 test. fFisher’s exact test. gt-test. 
ABI = ankle–brachial index. BMI = body mass index. BP = blood pressure. CHD = coronary heart disease. CV = cardiovascular. ECQ = Edinburgh Claudication Questionnaire. 
HDL = high-density lipoprotein. LDL = low-density lipoprotein. PAD = peripheral arterial disease. 
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Figure 2. QRISK2 score for participants with 
PAD. CV = cardiovascular. PAD = peripheral 
arterial disease. 
• pulse pressure (P<0.01); 
• rheumatoid arthritis (P = 0.019);
• QRISK2 score (P<0.01)
• positive ECQ result (P<0.01); and 
• the presence of ≥1 clinical sign of PAD 
(P<0.01). 
The number needed to screen (NNS) 
to detect one new case of PAD was 31. 
Refining the study population to those aged 
≥50 years with a history of smoking (ex- or 
current smoker), based on factors found to 
be significantly associated with PAD, would 
have reduced the NNS to 14, while still 
identifying 100% of the individuals with PAD.
The QRISK2 score predicted a high CV 
risk (defined by a QRISK2 score of ≥20) 
in 92% (n = 11) of participants with PAD 
(Figure 2). 
DISCUSSION
Summary
Although, globally, there is no shortage 
of studies investigating the prevalence of 
PAD, this PIPETTE study is the first UK 
study of PAD prevalence undertaken for 
9 years.17–19 The attained prevalence rate 
of 3% was lower than anticipated, given 
the social and health demographics of the 
area in which the study was undertaken. 
A targeted screening population, aged 
≥50 years with a history of smoking, would 
provide an effective and efficient screening 
strategy (NNS = 14), which also concurs 
with recommendations from the American 
College of Cardiology Foundation (ACCF) 
and the American Heart Association (AHA).3 
However, as QRISK2 predicted high CV risk 
in 92% of participants with PAD, it appears 
that the effect of adding the ABI to the 
QRISK2 algorithm, as an additional risk 
parameter, would be minimal. 
A third of participants with PAD had severe 
symptoms of intermittent claudication 
that warranted subsequent endovascular 
intervention, but had not presented to a 
doctor. This fact suggests a lack of public 
awareness of the disease and its symptoms.
Strengths and limitations 
This single-centre study with a relatively 
small sample size reduces the 
generalisability of the findings. In addition, 
all participants were of white British 
origin and, as such, are unrepresentative 
of the UK population. This lack of ethnic 
diversity could, in part, be due to the fact 
that only 3% of the population of Merthyr 
Tydfil (compared with 19.5% for England 
and Wales) is of non-white and non-British 
origin.20,21 Furthermore, this could have 
affected results as rates of CVD are known 
to be higher in people of South Asian and 
African Caribbean origin, for example.22 
One aspect of the design of this 
study — home participation — could be 
considered both a strength and a limitation. 
Allowing participants to take part at home 
could have increased the recruitment of 
those with mobility problems, transport 
issues, or caring duties for family 
members. This could have resulted in 
improved epidemiological data in terms 
of acquiring PAD prevalence rates that 
are more accurate. Conversely, however, 
incorporating home visits into the study 
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design could have meant that the resultant 
study population was not representative of 
those individuals who would ordinarily be 
likely to come forward for health service 
PAD screening undertaken in a healthcare 
setting. This could mean the results may 
not be transferable or applicable to an 
actual screening programme. Furthermore, 
recruitment bias, with individuals who are 
more health conscious being more likely to 
agree to take part than those who are less 
health conscious, was also possible.
Despite its limitations, this study serves 
to add to the evidence base regarding the 
epidemiology of PAD in the UK and globally. 
Comparison with existing literature
PAD prevalence. Comparing the attained 
PAD prevalence rate of 3% with existing 
data is hindered by the fact that studies use 
different methods for calculating the ABI. 
Although several studies screened similar 
populations as this PIPETTE study in terms 
of excluding those with pre-identified 
CVD,22–25 only two (the Multi-Ethnic Study 
of Atherosclerosis [MESA] and PANDORA 
studies25,26) calculated the ABI using the 
standard calculation as recommended by 
the AHA.16
In the US, the MESA study, which screened 
1932 individuals aged 45–84 years, who 
were free of known clinical CVD, returned a 
similar PAD prevalence of 3.4%.25 However, 
the pan-European PANDORA study of 9816 
individuals, with no known CVD or diabetes, 
reported a higher prevalence of 17.8%.26 
The PANDORA study differed from the 
MESA study in that its inclusion criteria 
specified that participants must have ≥2 
CV risk factors, which may account for 
some of the discrepancy in prevalence rates 
between those two studies. The PIPETTE 
prevalence rate is much closer to that of 
the MESA study, despite the fact that its 
inclusion and exclusion criteria are almost 
identical to those of the PANDORA study. 
Prevalence rates of British studies range 
from 8.0–10.8% but, again, differing study 
populations and ABI calculation methods 
make comparisons difficult.17–19
Who should PAD screening target? The 
suggested PAD screening target population 
of people aged ≥50 years with a history of 
smoking concurs with that recommended 
by the ACCF/AHA Task Force’s PAD 
guidelines.3 Adhering to the UK PAD 
guideline formulated by the National 
Institute for Health and Care Excellence — 
which recommends screening people with 
diabetes and those with symptoms of PAD 
or non-healing leg wounds — would have 
resulted in an NNS of 3, with only 42% of 
PAD cases being identified.5 
In comparison with existing screening 
programmes in the UK, the proposed 
screening target population for PAD would be 
more efficient in terms of the yield of positive 
cases. The NNS to detect one new case of 
PAD (NNS = 14) is less than the reported 
NNS to detect one positive case associated 
with current bowel screening (NNS = 50)27 
and breast screening (NNS = 125)28 
programmes. Though, of course, the 
true value of a screening programme is 
better assessed via consideration of the 
NNS for a given duration to prevent one 
death or adverse event. That information 
is derived from randomised control trials 
(RCTs) of screening versus no screening, 
of which there is none currently published 
in relation to PAD. It should be noted, 
however, that data from the Viborg Vascular 
PAD screening RCT, including all-cause 
and CVD mortality, should be available in 
late 2018.29
Cardiovascular risk prediction. Some 
studies have questioned the value of 
adding the ABI to CV risk algorithms.7 
Murphy et al examined the predictive 
ability of ABI compared with the FRS by 
conducting a post-hoc analysis of data 
from the ARIC (Atherosclerosis Risk in 
Communities) Study;30 they concluded 
that the independent effect of ABI when 
adjusted for the FRS was small and did 
not support FRS modification to include 
ABI. Newer CV risk scoring systems such 
as the Joint British Societies’ consensus 
(JBS3) and QRISK2 are considered 
improvements on the FRS as a result of 
their incorporation of additional risk factors 
such as ethnicity, family history, and social 
deprivation; notably, however, no studies to 
date have assessed the contribution of the 
ABI to these superior CV scoring tools.31 
The UK National Screening Committee 
highlights that a major drawback of CV risk 
assessment algorithms concerns missing 
or out-of-date data, which may reduce their 
accuracy and undermine confidence in 
predictive ability.9
Lack of public awareness of PAD. Existing 
studies have also reported a lack of 
public awareness of PAD; according to 
Norgren et al, population studies have 
consistently shown that 10–50% of patients 
with intermittent claudication have never 
consulted a doctor.32 Studies by Hirsch et 
al and Lovell et al, conducted in the US 
and Canada respectively, demonstrated 
that approximately two-thirds of people 
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surveyed had never heard of PAD;33,34 in 
Hirsch et al’s study, of those who were 
aware of it, half or fewer were unaware that 
smoking (44%) and diabetes (50%) could 
lead to PAD.33 Results from the PIPETTE 
study appear to suggest that this apparent 
lack of awareness of PAD also applies in the 
UK and has not improved in recent years. 
Implications for research and practice 
This PIPETTE study provides evidence 
that routine primary care PAD screening 
in a non-diabetic population is not 
worthwhile. However, larger-scale studies 
that incorporate a population derived 
from multiple general practices and 
that is ethnically diverse are required to 
corroborate results.
With regard to identification of individuals 
at high CV risk, it appears that the QRISK2 
algorithm is largely comparable to the 
ABI, with the former being far more 
amenable for use in busy general practice 
settings. As most CV risk algorithms are 
now incorporated into general practice 
electronic health record systems, with new 
information, such as an updated blood 
pressure, being automatically processed to 
continually update the risk score, a health 
professional can determine a patient’s 
score at the touch of a button. In contrast, 
ABI measurement can be impaired by 
issues relating to its practicality and the 
requisite operator skill at using the hand-
held Doppler.35
This study suggests that there is room 
for improvement in the primary care 
diagnosis of symptomatic PAD. This could 
be achieved by clinicians simply asking 
about claudication symptoms during 
routine consultations. Effective strategies to 
raise public awareness of this little known 
disease are also needed. On a simplistic 
level, this could involve displaying PAD 
posters in general practice waiting rooms 
and pharmacies; more sophisticated 
strategies, via social media, for example, 
could also be developed and implemented. 
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